Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03269578 · ClinicalTrials.gov registry record
Sample Collection and Tracking for the Developmental Therapeutics Clinic
A clinical trial of Lymphoma and Neoplasms, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT03269578: Recruiting study of Lymphoma and Neoplasms, sponsored by National Cancer Institute (NCI).
NCT03269578 is a study of Lymphoma and Neoplasms that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 3,000 participants, above the 474-participant average among 299 other Lymphoma trials with a reported enrollment target (533% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03269578, a study of Lymphoma and Neoplasms, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: People who join a study in the Developmental Therapeutics Clinic (DTC) have tests. These include blood draws and biopsies. Researchers collect data from these samples. Some people take part in more than one study at the DTC. At this time, data are connected only with one single study. Researchers want to access people s medical records. This will allow them to link the research data from all their studies they have or will take part in. Researchers also want to collect medical data about their diagnosis and treatment history. This will allow them to see how their cancer reacted to different drugs over time. Objective: To enter people into a master protocol to connect research sample and treatment data across DTC studies. Eligibility: People ages 18 and older who are being evaluated or treated for cancer in the DTC Design: Participants will allow researchers to look at all the data from their research samples. This includes those from their current, past, and any future NIH studies. Participants will allow researchers to access some of their medical data. This includes age, diagnosis, treatment history, and response to treatment. Participants will provide no new samples. ...
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2017-08-28 |
| Est. Completion | 2027-05-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03269578
The ClinicalTrials.gov registry entry for NCT03269578 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 474-participant average among 299 other Lymphoma trials with a reported enrollment target (533% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT03269578 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03269578 about?
NCT03269578 is a clinical study titled "Sample Collection and Tracking for the Developmental Therapeutics Clinic". Background: People who join a study in the Developmental Therapeutics Clinic (DTC) have tests. These include blood draws and biopsies. Researchers collect data from these samples. Some people take part in more than one study at the DTC. At this time, data are connected only with one single study. R...
What is the current status of trial NCT03269578?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2017-08-28. Estimated completion is 2027-05-30.
What conditions does trial NCT03269578 study?
This clinical trial studies the following conditions: Lymphoma, Neoplasms.
Who is sponsoring clinical trial NCT03269578?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03269578 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.